NI Technology Research Updates Outlooks for Merck, Pfizer, Vanguard Health Care, EZchip, Procera Networks, and DuPont Fabros Tec
07 Mai 2009 - 3:17PM
PR Newswire (US)
PRINCETON, N.J., May 7 /PRNewswire/ -- Next Inning Technology
Research (http://www.nextinning.com/), an online investment
newsletter focused on semiconductor and technology stocks,
announced it has previewed earnings for Merck (NYSE:MRK), Pfizer
(NYSE:PFE), Vanguard Health Care (NASDAQ:VGHCX), Procera Networks
(AMEX:PKT), DuPont Fabros Technology (NYSE:DFT), and many others.
On March 9th McWilliams wrote to Next Inning subscribers that the
rally would start that week; he even described the catalysts that
would ignite it. Since that date, the Next Inning model portfolio
has gone up an additional 24% bringing its year to date gains to
37%, well ahead of the Nasdaq return of 12%. Since publishing his
special report last December, Undervalued Tech Stocks for 2009,
he's introduced his readers to almost a dozen stocks that have
doubled. To read what McWilliams thinks we should expect going
forward and where he thinks investors can still find big winners,
read his new Strategy Review. In it he explains why certain stocks
have jumped in some cases over 200%, what sectors will remain hot
and which ones will heat up during the second half. To gain
immediate access to this report and McWilliams' regular updates,
please accept our invitation to take a free 21-day no risk test
drive with Next Inning by visiting the following link:
https://www.nextinning.com/subscribe/index.php?refer=prn820
McWilliams covers these topics: -- DuPont Fabros Technology is up
roughly 375% since McWilliams said there were ample reasons for
speculation in the stock in a December report. Should investors
hold on for more gains or take profits? Could the stock still
double again from here? -- Where does Procera Networks fit into the
deep packet inspection food chain? Should investors be concerned
about the company's balance sheet? -- Would McWilliams put a health
care investment allocation in big pharmaceutical names like Pfizer
and Merck or does he prefer a broader approach like the Vanguard
Health Care Fund? Founded in September 2002, Next Inning's model
portfolio has returned 182% since its inception versus 36% for the
Nasdaq. About Next Inning: Next Inning is a subscription-based
investment newsletter that provides regular coverage on more than
150 technology and semiconductor stocks. Subscribers receive
intra-day analysis, commentary and recommendations, as well as
access to monthly semiconductor sales analysis, regular Special
Reports, and the Next Inning model portfolio. Editor Paul
McWilliams is a 25+-year semiconductor industry veteran. NOTE: This
release was published by Indie Research Advisors, LLC, a registered
investment advisor with CRD #131926. Interested parties may visit
adviserinfo.sec.gov for additional information. Past performance
does not guarantee future results. Investors should always research
companies and securities before making any investments. Nothing
herein should be construed as an offer or solicitation to buy or
sell any security. CONTACT: Marcia Martin, Next Inning Technology
Research, +1-888-278-5515 DATASOURCE: Indie Research Advisors, LLC
CONTACT: Marcia Martin of Next Inning Technology Research,
+1-888-278-5515 Web Site: http://www.nextinning.com/
Copyright
Procera Networks, Inc. (AMEX:PKT)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Procera Networks, Inc. (AMEX:PKT)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
Real-Time news about Procera Networks, Inc. (American Stock Exchange): 0 recent articles
Plus d'articles sur Procera Networks,